ATE385781T1 - Montelukast-granulatformulierung - Google Patents

Montelukast-granulatformulierung

Info

Publication number: ATE385781T1
Authority: AT; Austria
Prior art keywords: montelukast; granular formulation; granular; formulation; relates
Prior art date: 2001-10-26

Application number

AT02801836T

Other languages

English (en)

Inventor

Brian Down

Original Assignee

Merck Frosst Canada Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-26

Filing date

2002-10-22

Publication date

2008-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23329547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE385781(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-10-22 Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd

2008-03-15 Application granted granted Critical

2008-03-15 Publication of ATE385781T1 publication Critical patent/ATE385781T1/de

Links

UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
229960005127 montelukast Drugs 0.000 title 1
229960001951 montelukast sodium Drugs 0.000 abstract 1
LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 abstract 1
229940095353 oral granules Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Biophysics (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

AT02801836T 2001-10-26 2002-10-22 Montelukast-granulatformulierung ATE385781T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33954901P	2001-10-26	2001-10-26

Publications (1)

Publication Number	Publication Date
ATE385781T1 true ATE385781T1 (de)	2008-03-15

Family

ID=23329547

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02801836T ATE385781T1 (de)	2001-10-26	2002-10-22	Montelukast-granulatformulierung

Country Status (26)

Country	Link
US (2)	US20030096840A1 (de)
EP (1)	EP1441701B1 (de)
JP (1)	JP4420671B2 (de)
KR (1)	KR101094084B1 (de)
CN (1)	CN100591329C (de)
AT (1)	ATE385781T1 (de)
AU (1)	AU2002333134B2 (de)
BR (1)	BR0213477A (de)
CA (1)	CA2463947C (de)
CY (1)	CY1107400T1 (de)
DE (1)	DE60225040T2 (de)
DK (1)	DK1441701T3 (de)
EC (1)	ECSP045082A (de)
EG (1)	EG24380A (de)
ES (1)	ES2298431T3 (de)
HR (1)	HRP20040367B1 (de)
HU (1)	HUP0401670A3 (de)
IL (1)	IL161299A0 (de)
MX (1)	MXPA04003856A (de)
MY (1)	MY148466A (de)
NO (1)	NO20042167L (de)
PE (1)	PE20030638A1 (de)
PT (1)	PT1441701E (de)
SI (1)	SI1441701T1 (de)
WO (1)	WO2003035036A1 (de)
ZA (1)	ZA200402584B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040192660A1 (en) *	2003-03-12	2004-09-30	Mullally John P.	Protocol for improving vision
MX2007011273A (es) *	2005-03-16	2007-11-08	Meda Pharma Gmbh & Co Kg	La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
CN100500149C (zh) *	2005-06-22	2009-06-17	晟德大药厂股份有限公司	白三烯素拮抗剂口服液组成
CA2629904C (en)	2005-11-28	2018-07-10	Imaginot Pty Ltd.	Oral therapeutic compound delivery system
PT1976522E (pt)	2005-12-30	2013-09-09	Krka Tovarna Zdravil D D Novo Mesto	Composição farmacêutica contendo montelucaste
CA2635841A1 (en) *	2006-02-09	2007-08-16	Teva Pharmaceutical Industries Ltd.	Stable pharmaceutical formulations of montelukast sodium
CN101516334B (zh)	2006-09-26	2013-07-10	塔罗制药北美有限公司	用于抗生素的稳定组合物以及应用方法
CN102046202A (zh) *	2008-03-26	2011-05-04	塔罗制药北美有限公司	用于口服药剂的稳定脂质组合物
US20100286045A1 (en)	2008-05-21	2010-11-11	Bjarke Mirner Klein	Methods comprising desmopressin
US11963995B2 (en)	2008-05-21	2024-04-23	Ferring B.V.	Methods comprising desmopressin
SI2712622T1 (sl)	2008-05-21	2016-10-28	Ferring B.V.	Orodisperzibilni dezmopresin za povečanje začetnega obdobja spanja nemotenega z nokturijo
WO2009153305A2 (en) *	2008-06-19	2009-12-23	Sandoz Ag	Pharmaceutical compositions of montelukast sodium
US8895141B2 (en)	2008-08-18	2014-11-25	Mitsubishi Shoji Foodtech Co., Ltd.	Excipient for compressed tablets comprising novel spherical mannitol
MX341200B (es)	2010-03-29	2016-08-11	Ferring Bv	Composicion farmaceutica de disolucion rapida.
JO3112B1 (ar)	2010-03-29	2017-09-20	Ferring Bv	تركيبة دوائية سريعة التحلل
FR2967066B1 (fr) *	2010-11-04	2013-06-14	Ethypharm Sa	Utilisation par voie sublinguale de microgranules non comprimes
CN102085187B (zh) *	2011-01-27	2012-01-11	海南美大制药有限公司	孟鲁司特钠脂质体固体制剂
RU2605929C2 (ru)	2011-07-26	2016-12-27	Сан Фарма Адвансед Ресёрч Компани Лтд.	Производные хинолина и хиноксалина, полезные в качестве антагонистов цистеинил-лейкотриена
BR112014005134A2 (pt)	2011-09-16	2017-04-18	Ferring Bv	composição farmacêutica de dissolução rápida
WO2013077829A1 (en)	2011-11-21	2013-05-30	Mahmut Bilgic	Water-soluble pharmaceutical granules
EP3275466A1 (de) *	2012-07-12	2018-01-31	Ferring B.V.	Diclofenacformulierungen
WO2014012954A1 (en)	2012-07-18	2014-01-23	Takeda Gmbh	Treatment of partly controlled or uncontrolled severe asthma
US20140072628A1 (en) *	2012-09-12	2014-03-13	Glenmark Generics Ltd.	Stable pharmaceutical composition of saxagliptin
CN103520136B (zh) *	2013-10-15	2020-07-31	天垚医药科技发展（上海）有限公司	孟鲁斯特钠脉冲胶囊及其制备方法
CN103520129B (zh) *	2013-10-15	2020-07-31	天垚医药科技发展（上海）有限公司	一种孟鲁斯特钠脉冲释放制剂
CN103520130B (zh) *	2013-10-15	2020-08-04	天垚医药科技发展（上海）有限公司	孟鲁斯特钠择时控释片及其制备方法
CN104644564A (zh) *	2013-11-25	2015-05-27	天津汉瑞药业有限公司	一种含孟鲁司特钠的稳定的颗粒制剂及其制备方法
CN103655497B (zh) *	2013-12-18	2018-05-29	北京华禧联合科技发展有限公司	一种孟鲁司特钠口腔崩解片及其制备方法
EP3096760A1 (de)	2014-01-22	2016-11-30	Takeda GmbH	Behandlung von teilweise kontrolliertem oder unkontrolliertem schweren asthma mit einem pde4-inhibitor (und in kombination mit einem leukotrien-modifikator)
CN103720672B (zh) *	2014-01-26	2016-03-16	新疆特丰药业股份有限公司	孟鲁司特钠咀嚼片及其粉末直接压片制备方法
CN104840427B (zh) *	2014-02-13	2017-09-29	长春海悦药业股份有限公司	一种含有孟鲁司特钠的药物组合物
WO2016148455A2 (ko) *	2015-03-13	2016-09-22	경희대학교 산학협력단	몬테루카스트의 생체이용률을 개선시키기 위한 방법
JP6489435B2 (ja) *	2015-04-20	2019-03-27	高田製薬株式会社	モンテルカストナトリウム顆粒製剤
CN107595783A (zh) *	2017-06-01	2018-01-19	合肥远志医药科技开发有限公司	一种孟鲁司特钠颗粒及其制备方法
CN109833302A (zh) *	2017-11-29	2019-06-04	扬子江药业集团有限公司	一种稳定的孟鲁司特钠咀嚼片及其制备方法
CN110787139A (zh) *	2018-08-01	2020-02-14	北京万全德众医药生物技术有限公司	一种孟鲁司特钠药物组合物
US10966943B2 (en)	2018-09-06	2021-04-06	Innopharmascreen Inc.	Methods and compositions for treatment of asthma or parkinson's disease
CN111110679A (zh) *	2018-10-31	2020-05-08	长春海悦药业股份有限公司	一种含有孟鲁司特钠的药物组合物
CN111249238A (zh) *	2020-01-19	2020-06-09	安徽省先锋制药有限公司	一种孟鲁司特钠颗粒制剂方法
WO2022006470A1 (en)	2020-07-01	2022-01-06	Vanderbilt University	Methods of treatment for a kidney disease
WO2022011210A1 (en) *	2020-07-10	2022-01-13	Sean Downing	Treatment for severe acute respiratory illness associated with coronavirus
CN111840233B (zh) *	2020-07-29	2022-05-06	浙江诺得药业有限公司	一种孟鲁司特钠固体分散体、其制备方法及其应用
CN115770222B (zh) *	2021-09-05	2025-09-26	山东新时代药业有限公司	一种孟鲁司特钠颗粒剂及其制备方法
CN114224847B (zh) *	2021-12-07	2023-09-15	哈尔滨珍宝制药有限公司	一种孟鲁司特钠颗粒的制备方法
CN114425040A (zh) *	2022-02-24	2022-05-03	佑华医药科技有限公司	一种孟鲁司特钠颗粒的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1561301A (en) *	1976-01-02	1980-02-20	Beecham Group Ltd	Orally administrable pharmaceutical composition
NZ230763A (en) *	1988-09-27	1991-10-25	Takeda Chemical Industries Ltd	Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
ATE107854T1 (de) *	1988-09-30	1994-07-15	Rhone Poulenc Rorer Ltd	Pharmazeutisches granulat.
DE69005679T2 (de) *	1989-03-29	1994-06-23	Takeda Chemical Industries Ltd	Zusammensetzung mit einer Verbindung der Vitamin B-Gruppe und ihre Herstellung.
JP2800242B2 (ja)	1989-03-30	1998-09-21	大正製薬株式会社	粒剤の製造方法
US5565473A (en) *	1990-10-12	1996-10-15	Merck Frosst Canada, Inc.	Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
JP2820829B2 (ja)	1991-03-07	1998-11-05	武田薬品工業株式会社	有核散剤およびその製造方法
JPH0967247A (ja)	1995-08-31	1997-03-11	Taisho Pharmaceut Co Ltd	均一な微粒子製剤の製造方法
WO1997016173A1 (en) *	1995-11-02	1997-05-09	Merck Frosst Canada Inc.	New technology for wet granulation
NZ331160A (en) *	1996-02-08	2000-07-28	Merck & Co Inc	use of loratadine and a leukotriene antagonist to treat asthma
US5869098A (en) *	1997-08-20	1999-02-09	Fuisz Technologies Ltd.	Fast-dissolving comestible units formed under high-speed/high-pressure conditions
NZ520907A (en)	1997-12-23	2004-05-28	Schering Corp	Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6224907B1 (en) *	1998-03-06	2001-05-01	Alza Corporation	Anti-asthma therapy
US6221880B1 (en) *	1998-10-09	2001-04-24	Schering Corporation	Composition and method for treating allergic diseases
US6103735A (en) *	1998-10-09	2000-08-15	Schering Corporation	Composition and method for treating allergic diseases
AT413647B (de)	1998-11-26	2006-04-15	Sandoz Ag	Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6491949B2 (en) *	2000-01-14	2002-12-10	Osmotica Corp.	Osmotic device within an osmotic device
US20030031720A1 (en) *	2000-02-24	2003-02-13	Tobias Laich	Method for producing pharmaceutical dosage forms
US6316029B1 (en) *	2000-05-18	2001-11-13	Flak Pharma International, Ltd.	Rapidly disintegrating solid oral dosage form

2002
- 2002-10-17 MY MYPI20023875A patent/MY148466A/en unknown
- 2002-10-22 KR KR1020047006095A patent/KR101094084B1/ko not_active Expired - Lifetime
- 2002-10-22 HU HU0401670A patent/HUP0401670A3/hu unknown
- 2002-10-22 BR BR0213477-2A patent/BR0213477A/pt not_active Application Discontinuation
- 2002-10-22 DK DK02801836T patent/DK1441701T3/da active
- 2002-10-22 PT PT02801836T patent/PT1441701E/pt unknown
- 2002-10-22 IL IL16129902A patent/IL161299A0/xx unknown
- 2002-10-22 ES ES02801836T patent/ES2298431T3/es not_active Expired - Lifetime
- 2002-10-22 JP JP2003537603A patent/JP4420671B2/ja not_active Expired - Lifetime
- 2002-10-22 HR HRP20040367AA patent/HRP20040367B1/xx not_active IP Right Cessation
- 2002-10-22 CA CA002463947A patent/CA2463947C/en not_active Expired - Lifetime
- 2002-10-22 EP EP02801836A patent/EP1441701B1/de not_active Revoked
- 2002-10-22 SI SI200230670T patent/SI1441701T1/sl unknown
- 2002-10-22 DE DE60225040T patent/DE60225040T2/de not_active Expired - Lifetime
- 2002-10-22 AU AU2002333134A patent/AU2002333134B2/en not_active Expired
- 2002-10-22 WO PCT/CA2002/001604 patent/WO2003035036A1/en not_active Ceased
- 2002-10-22 CN CN02821212A patent/CN100591329C/zh not_active Expired - Lifetime
- 2002-10-22 AT AT02801836T patent/ATE385781T1/de active
- 2002-10-22 MX MXPA04003856A patent/MXPA04003856A/es active IP Right Grant
- 2002-10-23 EG EG2002101164A patent/EG24380A/xx active
- 2002-10-24 US US10/279,595 patent/US20030096840A1/en not_active Abandoned
- 2002-10-24 PE PE2002001047A patent/PE20030638A1/es active IP Right Grant
2004
- 2004-04-01 ZA ZA2004/02584A patent/ZA200402584B/en unknown
- 2004-04-23 EC EC2004005082A patent/ECSP045082A/es unknown
- 2004-05-25 NO NO20042167A patent/NO20042167L/no not_active Application Discontinuation
2008
- 2008-02-07 US US12/069,124 patent/US8007830B2/en not_active Expired - Fee Related
- 2008-04-17 CY CY20081100434T patent/CY1107400T1/el unknown

Also Published As

Publication number	Publication date
EP1441701B1 (de)	2008-02-13
CA2463947C (en)	2009-05-19
US20080131516A1 (en)	2008-06-05
ECSP045082A (es)	2004-06-28
HRP20040367B1 (en)	2012-07-31
US8007830B2 (en)	2011-08-30
CN1575163A (zh)	2005-02-02
JP2005510497A (ja)	2005-04-21
JP4420671B2 (ja)	2010-02-24
EP1441701A1 (de)	2004-08-04
PE20030638A1 (es)	2003-07-21
HRP20040367A2 (xx)	2005-06-30
DK1441701T3 (da)	2008-05-26
SI1441701T1 (sl)	2008-08-31
US20030096840A1 (en)	2003-05-22
MY148466A (en)	2013-04-30
AU2002333134B2 (en)	2007-08-02
DE60225040D1 (de)	2008-03-27
PT1441701E (pt)	2008-04-07
CN100591329C (zh)	2010-02-24
HUP0401670A2 (hu)	2008-05-28
WO2003035036A1 (en)	2003-05-01
KR101094084B1 (ko)	2011-12-15
ES2298431T3 (es)	2008-05-16
EG24380A (en)	2009-04-05
IL161299A0 (en)	2004-09-27
ZA200402584B (en)	2005-06-29
HUP0401670A3 (en)	2008-08-28
CA2463947A1 (en)	2003-05-01
KR20040047961A (ko)	2004-06-05
BR0213477A (pt)	2004-11-03
DE60225040T2 (de)	2009-02-26
CY1107400T1 (el)	2012-12-19
NO20042167L (no)	2004-05-25
MXPA04003856A (es)	2004-07-08

Legal Events

Date

Code

Title

Description

2008-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1441701

Country of ref document: EP

Publication	Publication Date	Title
DK1441701T3 (da)	2008-05-26	Montelukast-granuleformulering
SE0203713D0 (sv)	2002-12-13	Novel compounds
SG10201809390QA (en)	2018-11-29	Modulators of indoleamine 2,3-dioxygenase and methods of using the same
CO5590918A2 (es)	2005-12-30	Formulaciones
EA199900373A2 (ru)	1999-12-29	Фармацевтические композиции
ATE296619T1 (de)	2005-06-15	Feste orale dosierungsform von simethicon
SE0301700D0 (sv)	2003-06-10	Novel compounds
BR0207640A (pt)	2004-07-27	Composição farmacêutica oral de cefpodoxima proxetil
DK1458377T3 (da)	2006-06-12	Farmaceutiske sammensætninger indeholdende tegaserod
EA200300334A1 (ru)	2003-12-25	Новая соль периндоприла и содержащие ее фармацевтические композиции
UY27852A1 (es)	2003-12-31	Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
NO20043016L (no)	2004-07-15	6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
SE9901077D0 (sv)	1999-03-23	Novel use
SE0203825D0 (sv)	2002-12-20	Novel fused heterocycles and uses thereof
SE9801494D0 (sv)	1998-04-28	Novel use
SE0200657D0 (sv)	2002-03-04	Novel Formulation
DE60316128D1 (de)	2007-10-18	N-sulfonylurea-apoptosis-förderer
MXPA04004090A (es)	2004-07-08	Compuestos substituidos de 1h-quinolin-2-ona.
MXPA04003297A (es)	2004-07-23	Derivados novedosos de benzotiacina su preparacion y uso.
NO20024880L (no)	2003-09-22	Sammensetning inneholdende fosfat
NO20024679D0 (no)	2002-09-30	Krystallinsk farmasöytikum
RS20060016A (en)	2008-06-05	Semi-solid systems containing azetidine derivatives
GB0309440D0 (en)	2003-06-04	Quinolone derivatives
NO20035138D0 (no)	2003-11-18	Fremgangsmåte til fremstilling av amorft natriumsilastatin
DE60102704D1 (de)	2004-05-13	Trioxepan verbindungen